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Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a 
dopamine agonist instead of levodopa delays the occurrence of motor complications.  This 5-year 
prospective,  open,  multicenter randomized study aimed to compare the eﬀects of cabergoline on the 
onset of motor complications with those of levodopa in Japanese patients with early PD.  Patients who 
had never been treated with dopamine agonists or levodopa were enrolled in this study.  Four of 45 
patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor compli-
cations.  The estimated cumulative incidence of motor complications in the cabergoline and levodopa 
groups was 17ｵ and 34ｵ (hazard ratio,  0.57; 95ｵ conﬁdence interval,  0.18‒1.81; p＝0.347).  Thirty-
ﬁve adverse events (AEs) were reported in 24 patients in the cabergoline group,  while 16 AEs were 
reported in 13 patients in the levodopa group.  Patients in the cabergoline group showed fewer motor 
complications than did those in the levodopa group,  although the diﬀerence was not statistically sig-
niﬁcant.  However,  the hazard ratio found in this study was similar to those in previous reports.
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arkinsonʼs disease (PD) is a chronic and pro-
gressive neurodegenerative disorder character-
ized by the classic motor symptoms of tremor,  rigid-
ity,  bradykinesia,  and postural instability.  The annual 
incidence of PD in the Japanese population was 
16.9/100,000 in 1997 [1].  In addition,  the annual 
incidence was 1.8-fold higher in 2004 when compared 
with that in 1980 because of the aging of the popula-
tion [2].  Although symptomatic therapy for PD is 
usually eﬀective for several years,  the disorder slowly 
progresses and ﬁnally results in impaired quality of 
life (QOL) with signiﬁcant disability.
　 Since the 1960s,  dopamine replacement therapy 
using levodopa has been the most eﬀective choice of 
treatment for PD despite the development of motor 
complications like dyskinesia,  wearing oﬀ,  and on-oﬀ 
motor ﬂuctuations after a few years of therapy [3].  
Recently,  initial therapy with a dopamine agonist has 
been proposed in patients with early PD [4] on the 
basis of reports demonstrating that initial therapy 
with a dopamine agonist,  and not levodopa,  delayed 
the onset of dyskinesia [5-7],  wearing oﬀ,  and on-oﬀ 
motor ﬂuctuations [5-10] during long-term treatment.  
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The PD treatment guidelines updated in 2002 sug-
gested that either levodopa or a dopamine agonist can 
be used for patients requiring initiation of symptom-
atic therapy [11].  However,  to the best of our 
knowledge,  a long-term study comparing the eﬀective-
ness of a dopamine agonist with that of levodopa has 
not yet been conducted in Japanese patients with early 
PD.
　 The aim of the present postmarketing study in 
Japanese patients with early PD was to evaluate 
whether initial treatment with a long-acting dopamine 
receptor agonist,  cabergoline,  caused fewer motor 
complications during the long-term treatment period 
than those caused by treatment with levodopa.
Subjects and Methods
　 Subjects. One hundred ﬁfty-six patients were 
initially considered for participation in the study.  
Male and female patients aged between 40 and 70 
years with a clinical diagnosis of PD and a Hoehn and 
Yahr stage [12] of I,  II,  or III were enrolled at 13 
institutions.  These patients had never been treated 
with any dopamine agonists or levodopa.  Patients 
were excluded if they had severe hepatic,  renal,  or 
orthopedic dysfunction or symptomatic dementia,  or if 
they were pregnant.  The study patients were then 
randomly assigned to either the initial cabergoline 
treatment arm or initial levodopa treatment arm by N 
Yamaguchi,  MD,  PhD.  The protocol was approved by 
an ethics committee at each institution.  Written 
informed consent was obtained from each patient.
　 The ﬁrst patient visits were scheduled for the 2nd 
week,  followed by every 4 weeks for the ﬁrst 4-24 
weeks,  and every 3 months thereafter.
　 Treatment. Open-label cabergoline and levodopa 
treatments were initiated with doses of 0.25-2mg 
once daily and 100-300mg/day 2-3 times daily.  The 
dosage was then titrated to a maintenance dose of up 
to 6mg/day for cabergoline and 600mg/day for 
levodopa.  In cases in which the lowest Uniﬁed 
Parkinsonʼs Disease Rating Scale (UPDRS) score 
[13] worsened by more than 30ｵ during the ﬁrst 
12-24 weeks of study treatment,  the dosage was 
titrated up to 6mg/day cabergoline or 600mg/day 
levodopa.  If the investigator judged it necessary to 
start additional therapy for PD because of medical 
reasons,  levodopa (after the cabergoline dose was 
titrated to more than 4mg once daily) and cabergoline 
were added to the initial cabergoline and levodopa 
groups.  Administration of selegiline and dopamine 
agonists other than cabergoline was prohibited.  
Administration of anticholinergics and amantadine was 
permitted prior to study enrollment only.  After onset 
of the primary endpoint,  administration of any anti-
PD drug was permitted.
　 Outcomes. The primary endpoint was the 
development of motor complications (dyskinesia,  
wearing oﬀ,  or on-oﬀ motor ﬂuctuations).  The pres-
ence or absence of motor complications was assessed 
by each investigator at every patient visit.  The sec-
ondary endpoints were the patientʼs physical and 
mental status as evaluated by UPDRS and doses of 
study drugs at the end of the study.  These outcomes 
were subjective; therefore,  double or single blinding 
was the preferred design for this type of study [14].  
However,  our limited resources did not permit treat-
ment with a placebo.  In addition,  since the assessment 
of outcomes by nonattending physicians at every 
patient visit could harm the patientsʼ relationships with 
the researchers,  we were compelled to use an open 
design.
　 Cardiac valve regurgitation substudy. During 
the patientsʼ follow-up periods,  the risk of cardiac 
valvulopathy was reported in PD patients treated with 
ergot-derived dopamine agonists [15-19].  In June 
2007,  we decided to conduct a substudy to evaluate 
the level of cardiac valvular regurgitation in our study 
patients.  Informed consent was again obtained from 
the patients enrolled in the initial cabergoline group,  
and echocardiography was performed for these patients.  
Abnormalities in the cardiac valves were quantiﬁed by 
each study investigator in the following manner:  
absent (grade 0),  trace (grade 1),  mild (grade 2),  
moderate (grade 3),  and severe (grade 4).  The regur-
gitation data obtained from this substudy was not 
included in the adverse event (AE) data,  because this 
type of examination is not routinely performed for 
asymptomatic patients.
　 Statistical analysis. The cumulative incidence,  
between-group statistical diﬀerences,  and hazard ratio 
of the primary outcome were calculated by the Kaplan-
Meier method,  logrank test,  and unadjusted Cox 
proportional hazards regression model,  respectively.  
Changes in UPDRS scores between baseline and the 
end of follow-up were analyzed using repeated mea-
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sures analysis of variance with adjustments for the 
corresponding baseline absolute score.  Missing values 
were replaced by the last-observation-carried-forward 
method.  The diﬀerence between the 2 groups was 
assessed by the Wilcoxon signed-rank test or Fisherʼs 
exact test.  All statistical tests were two-sided,  and a 
5ｵ level of signiﬁcance (p＜0.05) was applied.
Results
　 Patient characteristics. A total of 98 patients 
were enrolled between April 2002 and November 
2003 (Fig.  1).  These patients were randomly allo-
cated to either the initial cabergoline group (n＝49) or 
the initial levodopa group (n＝49).  Patients excluded 
from the analysis included 4 from the cabergoline 
group (2 for not following up,  1 for not taking any 
study drug,  and 1 for withdrawal of consent) and 3 
from the levodopa group (1 for not taking any study 
drug and 2 for diagnosis of non-PD after randomiza-
tion).
　 The ratio of males was slightly higher in the caber-
goline group than in the levodopa group (p＝0.0598,  
Table 1).  The baseline UPDRS mental subscore was 
lower in the cabergoline group than in the levodopa 
group (p＝0.0327).
　 Patient follow-up and treatment. In the ini-
tial cabergoline group,  treatment was initiated with 
0.25mg/day cabergoline in 29 patients,  0.5mg/day in 
13 patients,  and a higher dosage (1-2mg/day) in 3 
patients.  In the initial levodopa group,  treatment was 
initiated with 50mg/day levodopa in 4 patients,  
100mg/day in 35 patients,  and a higher dosage (200-
300mg/day) in 7 patients.  Twelve patients in the ini-
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Enrollment (98)
Cabergoline group (49) Levodopa group (49)
Exclusion (4)
• No data (2)
• Withdrawal of consent (2)
Exclusion (3)
• No data (1)
• Multiple system atrophy (2)
Analysis set (45)
Prematurely withdrew (33)
• Adverse events (11)
• Lack of efﬁcacy (6)
• Lost to follow-up (12)
• Other reason (4)
Completed the study (12)
Analysis set (46)
Prematurely withdrew (19)
• Adverse events (2)
• Lack of efﬁcacy (3)
• Lost to follow-up (10)
• Other reason (4)
Completed the study (27)
Fig. 1　 Random assignment to treatment,  completion of the trial,  
and the reasons for not completing the trial.  (　)＝number of 
patients.
Table 1　 Demographic and disease severity at baseline of the study subjects with early Parkinsonʼs disease with cabergoline or 
levodopa as initial therapy
Patient Characteristics Cabergoline (n＝45) Levodopa (n＝46)
Age (years old) 62.0±6.7 62.6±6.8
Male,  n (%) 26 (57.8) 17 (37.0)
Time since diagnosis (years) 2.0±1.7 1.7±1.2
Body weight (kg) 57.2±10.3 58.9±13.2
Severity of disease
　Hoehn and Yahr stage,  n (%)
　　I/II/III 9 (20.0)/20 (44.4)/16 (35.6) 15 (32.6)/17 (37.0)/14 (30.4)
　Uniﬁed Parkinsonʼs Disease Rating Scale score
　　Total 30.6±14.7 26.9±13.8
　　Mental component 0.6±1.2 1.3±1.6
　　Activity of daily living component 8.6±4.6 7.7±4.8
　　Motor component 21.6±11.1 18.1±10.1
Pretreatment,  n (%)
　　　Trihexyphenidyl 6 (13.3) 3 (6.5)
　　　Amantadine 8 (17.8) 7 (15.2)
Mean ± SD
tial cabergoline group (5 were maintained on mono-
therapy) and 27 patients in the initial levodopa group 
(19 were maintained on monotherapy) completed the 
planned 5-year study period.  The median follow-up 
duration was 30.0 months (interquartile range [IQR],  
9.0-54.0 months) in the initial cabergoline group and 
48.0 months (IQR,  25.5-60.0 months) in the initial 
levodopa group.  The daily dosage of cabergoline at the 
ﬁnal visit was 0.25-6mg/day (mean ± standard devia-
tion,  2.9±1.5mg/day) in the initial cabergoline group 
and 0.25-5mg/day (1.6±1.3mg/day,  13 patients) in 
the initial levodopa group.  The daily dosage of 
levodopa was 100-700mg/day (325±162mg/day,  20 
patients) in the initial cabergoline group and 100-
900mg/day (336±135mg/day) in the initial levodopa 
group.
　 Motor complications. Four motor complica-
tions were reported in the initial cabergoline group (2 
occurred after levodopa was added) and 11 in the ini-
tial levodopa group (none occurred after cabergoline 
was added).  The estimated cumulative incidence of 
motor complications was 17ｵ (95ｵ conﬁdence inter-
val [CI],  0-33) in the initial cabergoline group and 
34ｵ (95ｵ CI,  15-49) in the initial levodopa group 
(Fig.  2).  The hazard ratio was 0.57 (95ｵ CI,  0.18-
1.81; p＝0.347).  Dyskinesia,  wearing oﬀ,  and on-oﬀ 
motor ﬂuctuations were reported in 0,  4,  and 2 
patients,  respectively,  in the initial cabergoline group 
and 3,  11,  and 0 patients,  respectively,  in the initial 
levodopa group.
　 Uniﬁed Parkinsonʼs disease rating scale.
In both treatment groups,  the activities of daily living 
(ADL) score,  motor UPDRS score,  and total of the 
scores slowly decayed with time after the initial dras-
tic improvements (Fig.  3).  The changes in the ADL,  
motor UPDRS and total scores from baseline to 60 
months were not signiﬁcantly diﬀerent between the 
initial cabergoline and levodopa groups (p＝0.280,  p
＝0.398,  and p＝0.140,  respectively).
　 Hoehn and Yahr stage. The changes in the 
Hoehn and Yahr stage from the baseline did not diﬀer 
between the initial cabergoline group and the initial 
levodopa group (1-point decrease,  4 and 7 patients;  
no change,  29 and 27 patients; 1-point increase,  8 
and 8 patients; and 2-point increase,  4 and 4 patients,  
respectively; p＝0.848).
　 Adverse events. Thirty-ﬁve AEs were reported 
in 24 patients in the initial cabergoline group,  whereas 
16 AEs were reported in 13 patients in the initial 
levodopa group (Table 2).  The incidence of AEs was 
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Fig. 2　 Kaplan-Meier plots for the estimated cumulative probability of developing the ﬁrst conﬁrmed motor complication in the initial 
cabergoline treatment arm and initial levodopa treatment arm.
higher in the initial cabergoline group than in the ini-
tial levodopa group (p＝0.019).  The most frequent AE 
was edema.  There were 8 cases of serious AEs: 3 
malignant neoplasms (2 in the initial cabergoline and 1 
in the initial levodopa group),  1 suicide attempt in the 
initial levodopa group,  and 1 instance of melena,  1 of 
fracture and pneumonia together,  1 of cerebral hem-
orrhage,  and 1 of gallstone in the initial cabergoline 
group.
　 Cardiac valvular regurgitation substudy.
The cardiac valve function of 16 patients (7 males and 
9 females,  aged 47-70 years at enrollment) in the 
initial cabergoline group was evaluated by echocar-
diography.  Moderate (4 aortic and 1 aortic and mitral) 
and severe (1 aortic) valvular regurgitations were 
detected in 6 of 16 patients (37.5ｵ) (Table 3).  One 
patient in which moderate aortic and mild mitral 
regurgitation was detected had mitral regurgitation 
and hypertension at enrollment,  and another patient 
with moderate aortic and mitral regurgitation had a 
history of myocardial infarction.  There were no marked 
diﬀerences in sex,  age at examination,  cabergoline 
treatment term,  and cumulative doses of cabergoline 
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Fig. 3　 Changes in the mean Uniﬁed Parkinsonʼs Disease Rating Scale from baseline through month 60 in the initial cabergoline treat-
ment arm and initial levodopa treatment arm.
Time,  Group,  and T＊G are p-values of time,  group,  and interaction,  respectively,  by repeated measures analysis of variance with adjust-
ments for the corresponding baseline absolute score.
Table 2　 Summary of adverse event in initial cabergoline treat-
ment arm and initial levodopa treatment arm
Adverse Event
Number of events
(% of patients)
Cabergoline
(n＝45)
Levodopa
(n＝46)
Edema 13 (28.9) 7 (15.2)
Gastrointestinal disorder 3 (6.7) 2 (4.3)
Malignant neoplasm＊ 2 (4.4) 1 (2.2)
Cardiac valvular regurgitation 3 (6.7) 0
Depression 1 (2.2) 2 (4.3)
Insomnia 1 (2.2) 1 (2.2)
Suicide attempt＊ 0 1 (2.2)
Melena＊ 1 (2.2) 0
Fracture & pneumonia＊ 1 (2.2) 0
Cerebral hemorrhage＊ 1 (2.2) 0
Gallstone＊ 1 (2.2) 0
Others 8 (15.6)§ 2 (4.3)
Total 35 (53.3)§ 16 (28.3)§
＊Serious event,  §Some patients had more than one adverse event.
among the subgroups when divided by valvular regur-
gitation grading,  except for the 1 patient who had 
severe valvular regurgitation.
Discussion
　 In the present study,  we have demonstrated that 
the occurrence of motor complications tended to be 
lower in the initial cabergoline group than in the initial 
levodopa group,  although the diﬀerence was not sta-
tistically signiﬁcant.  The hazard ratio obtained in this 
study (0.57) was similar to that reported in previous 
foreign studies (0.25-0.68) [5-10].  These results 
suggest that cabergoline delays the onset of motor 
complications,  even though the present results were 
not conclusive because they were not statistically sig-
niﬁcant.
　 The early use of a dopamine agonist is more eﬀec-
tive for reducing the onset of dyskinesia than reducing 
the onset of the wearing oﬀ and on-oﬀ motor ﬂuctua-
tions [6-9].  In our study,  only 3 patients (6.5ｵ) in 
the initial levodopa group demonstrated an onset of 
dyskinesia.  This incidence was lower than that 
reported in previous studies (21.2ｵ [10],  30ｵ [8],  
45ｵ [6],  43.8ｵ [7]),  and may be attributed to the 
lower daily levodopa dosage (mean of 336mg/day at 
the ﬁnal visit) compared with those in previous west-
ern reports (500-800mg/day).
　 As shown in Fig.  3,  the changes in total,  ADL,  
and motor UPDRS scores were not signiﬁcantly dif-
ferent between the 2 groups,  although the initial 
levodopa group had slightly less impairment than the 
initial cabergoline group.  This result was congruent 
with those of previous studies [6-9].
　 The AE rate in the initial levodopa group was 
lower than that in the initial cabergoline group (p＝
0.019).  Similarly,  a lower AE rate in the levodopa 
group has also been reported in studies comparing 
dopamine agonists with levodopa [7-9].  The slightly 
lesser improvement in UPDRS status (Fig.  3) and 
higher AE rate in the initial cabergoline group may 
have contributed to the higher dropout rate in this 
group (73ｵ) compared with that in the initial 
levodopa group (42ｵ).
　 Although we had no baseline or control data for 
comparison,  our cardiac valve regurgitation substudy 
revealed 6 patients with moderate or severe valvular 
regurgitation after undergoing about 4 years of caber-
goline treatment.  Only 2 of the 6 patients had risk 
factors [20] such as mitral regurgitation,  hyperten-
sion,  or myocardial infarction at enrollment.  The 
other 4 patients with aortic regurgitation had no risk 
factors for cardiac valvular regurgitation at baseline.  
A recently published report suggested that higher 
daily and cumulative doses have a strong association 
with valvular regurgitation [21].  In our study,  only 1 
patient was categorized as having severe valvular 
regurgitation.  This patient was treated with the high-
est cumulative cabergoline dose in this substudy 
(Table 3).  However,  3 patients who were treated with 
more than 6g of cabergoline also demonstrated mild 
(cumulative cabergoline dose,  6.71g and 6.41g) or 
absent (6.22g) valvular regurgitation.  Therefore,  we 
did not ﬁnd a clear association between cabergoline 
dose and valvular regurgitation.  Further investiga-
tions may be needed to determine this association.
　 The present results demonstrated a tendency of 
fewer motor complications in the initial cabergoline-
treated Japanese patients with early PD than in 
levodopa-treated patients,  but the diﬀerence was not 
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Table 3　 Summary of patient characteristics at baseline and results of echocardiographic evaluation in the patients with initial cabergo-
line treatment arm of cardiac valvulopathy substudy
Grade＊ (n＝16) Male (n) Age (y.o.) Term (months) Cabergoline (g) Calciﬁcation (n)
Absent (n＝2) 0 59.4±0.7 52.3±11.2 5.3±1.3 0
Trace (n＝2) 1 66.6±1.7 54.3±6.9 3.6±0.1 0
Mild (n＝6) 3 65.2±8.7 49.3±5.1 5.6±2.7 1
Moderate (n＝5) 3 67.6±6.4 53.4±3.4 3.4±1.8 1
Severe (n＝1) 0 71.3 42.1 7.4 0
Abbreviations: ＊Worst abnormality in aortic,  mitral,  tricuspid and pulmonary valve; Term,  months at evaluation after treatment 
started; Cabergoline,  cumulative cabergoline exposure.  Values are expressed as patient number or mean ± SD.
statistically signiﬁcant.  The calculated hazard ratio 
was 0.57,  suggesting a 43ｵ reduction in the risk of 
motor complications,  a value similar to those obtained 
in previous studies conducted in Western countries.
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